RVVTF and RSCF Penny Stocks on the Move

RVVTF and RSCF are two penny stocks on the move. We said back on November 2nd to buy the dip in RVVTF when the stock was trading at just $.15 a share, which you can read here. We said on December 8th to buy any dips in RSCF, which it then dropped to $.50 in just two days and you can read here.Those that follow us are now sitting on gains of 166% in RVVTF and 378% in RSCF. In this article, Insider Financial takes a look at what's driving the recent price action in RVVTF and RSCF and what we think is next for both stocks.

How to Trade OTC Stocks

First up, it's important to understand that trading OTC stocks are not the same as trading blue chips. As we have stressed repeatedly to our subscribers, the key to trading penny stocks is finding momentum BEFORE it happens and then be patient. We got our subscribers in early on TSNP, which you can read our latest here, ENZC, which you can read about here, and recently CBDD, which you can read here.Now, when we say that we find momentum BEFORE it happens, we are swing traders looking to position our subscribers BEFORE the move happens. This is where the big money is made and why so many of our subscribers are sitting on gains of over 8900% in ENZC and over 22,400% in TSNP. If you want to day trade, this is not the place for you.If you want to make a few hundred bucks and then lose a thousand dollars the next day, we hear Tim Sykes has plenty of openings.We always alert our subscribers first before we publish for our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here. We alert our subscribers with our best ideas before our regular readers.[embed]https://www.youtube.com/watch?v=qGz2QIxW6Nc[/embed]

RVVTF

This is what we said in our last write-up on RVVTF.

Revive Therapeutics remains one of the most undervalued companies trading on the OTC Markets. We first covered Revive in September when shares were trading at $.20 a share. The stock has slowly dropped since then. At current levels, Revive Therapeutics is not just cheap, it’s an absolute bargain.

RVVTF is running along with other psychedelic plays, which is being led by MMEDF, one of our top plays of 2020 with our subscribers now up 958% and which you can read here. With RVVTF, its Psilocybin business is an added bonus as it's also a COVID-19 treatment play. RVVTF Daily ChartRVVTF is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. In October, the company announced an update on its Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.RVVTF has committed to ten clinical sites across Florida, Texas, Nevada, Arizona, and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020. The interim analysis will determine the better performing Bucillamine dose arm for the remainder of the trial and future complementary studies evaluating it in more severe cases, thus making Bucillamine a potential treatment option.

What's Exciting About RVVTF

Here is what’s exciting about RVVTF.HOW MANY COMPANIES FOR UNDER $1 ARE CURRENTLY AT PHASE 3 FOR TESTING FOR COVID-19 TREATMENT?HOW MANY COMPANIES ARE APPROVED FOR TESTING AT PHASE 3 FOR COVID-19?HOW MANY PHASE 3 COVID-19 TESTING COMPANIES WERE FAST TRACKED BY FDA?RVVTF meets all 3 criteria.

Psilocybin Business

With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.Under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison, the Company has completed an oral thin-film strip product with psilocybin with dosage forms ranging between 1 mg and 20 mg and demonstrating its versatility through physio-chemical characterization (e.g. tensile strength of films) of bio comparable tannin-chitosan composite materials, dissolution and disintegration testing, and rate of psilocybin release from composites. Currently, technical and scientific data is being processed and finalized.What's exciting about RVVTF is there are a number of advantages and benefits of an orally dissolvable psilocybin thin film such as the rapid dissolving and onset of action to the bloodstream, the ease and convenience for patients to administer without the need of water, chewing, or swallowing, the potential of improved therapeutic outcomes and efficacy for underserved diseases and disorders including the flexibility to create accurate dosing and tasteful options.

RSCF

RSCF has been on a tear ever since being granted a patent by the United States Patent Office for an ultracold shipping and storage container for transportation by air that uses liquid nitrogen technology for cooling. RSCF Daily ChartThe large state-of-the-art shipping system could carry many thousands of doses of vaccines and utilizes the commercially proven Cryometrix patented cooling and freezing technology that has the flexibility to provide precise temperature control across a wide range of temperatures.The system accommodates payloads ranging from those requiring conventional refrigeration to specialty products such as COVID-19 and related vaccines that may require temperatures as low as -80° centigrade (-112° Fahrenheit). Systems can be configured to provide for short or long duration shipping cycles, making it an ideal choice for the cold chain management.This is significant because Pfizer’s vaccine requires it to be stored in cold temperatures. This is why RSCF is running. Simply put, there's an urgent need to transport the vaccines at ultra-cold temperatures. That is the company's specialty and penny stock speculators are piling in on this enthusiasm for RSCF.

RVVTF and RSCF Bottom Line

Congrats to all who got in on RVVTF and RSCF early. RSCF has had the bigger run and we don't see any sign of it slowing down; however, we would not chase here. Best off waiting for the dip.RVVTF is still trading below its 52-week high of $.50 a share. We believe the momentum is going to continue, especially with data from its Phase 3 trial coming. The potential catalyst(s) will keep a bid in RVVTF and squeeze the shorts.Either way, there's no shortage of runners on the OTC Markets. Now is a great time to be a penny stock trader.As always, good luck to all (except the shorts)!

WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!

Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.Image by Peter W from Pixabay